bearish
CStone Pharma (基石药业) IPO: Thoughts on Valuation (Part 2)
780 Views11 Feb 2019 14:15
CStone Pharma, a Wuxi Apptec related biotech company, plans to raise USD 300m to list on the Hong Kong Stock Exchange. In our previous insight...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- CStone Pharma's (基石药业) Lock-Up Expiry - Analysis of Potential Selling Shareholders15 Aug 2019
- CStone Pharma's (基石药业) Lock-Up Expiry - Lack of Material Newsflow for Core Drug Candidates14 Aug 2019
- CStone Pharma (基石药业) Post-IPO: Strong Debut but Lacks near Term Catalysts26 Feb 2019
- CStone Pharma (基石药业) IPO: Strong Assembly and Backing (Part 1)25 Jan 2019
- Innovent Biologics IPO Valuation: Surprisingly Grounded in Reality15 Oct 2018
x